The ITGB3 Knockout 786-O Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal cell population derived from the human renal cell adenocarcinoma line 786-O. This product supplies a loss-of-function model for ITGB3, the gene encoding integrin beta-3. The polyclonal format provides a heterogeneous pool of knockout cells, minimizing the influence of clonal selection and enabling consistent investigation of gene disruption effects within a kidney epithelial carcinoma context.
The 786-O host cell line was originally established from a primary clear cell renal cell carcinoma and serves as a widely used model for ccRCC. These adherent cells exhibit characteristic epithelial morphology and harbor mutations relevant to kidney cancer, including VHL deficiency, which contributes to their utility in studying hypoxia-driven and angiogenesis-dependent tumor biology. As a renal cell adenocarcinoma line, 786-O cells are particularly suited for dissecting molecular mechanisms of tumor progression and for evaluating targeted therapies in vitro.
ITGB3 encodes integrin ??3, which heterodimerizes with ITGAV to form the ??V??3 receptor. Upon binding to vitronectin, fibronectin, or other RGD-containing ECM ligands, it recruits talin-1 (TLN1), kindlin-3 (FERMT3), and paxillin (PXN) to activate FAK (PTK2) and Src kinase. Downstream signaling proceeds through PI3K/AKT and MAPK1/3 pathways. Transcriptional regulation by VEGF, TGF-??, HIF1A, SP1, and AP-1 controls ITGB3 expression, while its activity upregulates effectors such as AKT1, MMP2, and CCND1. Overall, ITGB3 drives cell adhesion, migration, invasion, and angiogenesis.
In the 786-O ccRCC model, ITGB3 fosters tumor progression by activating FAK/Src and PI3K/AKT signaling, which drives enhanced cell migration, invasion, and pro-angiogenic responses. Disruption of ITGB3 in these polyclonal knockout cells creates an ideal system for studying how integrin ??3 loss alters these oncogenic pathways, potentially revealing dependencies that can be targeted in metastatic renal cell carcinoma.
Typical applications include western blotting for phospho-AKT (Ser473) and MAPK1/3, cell adhesion assays on vitronectin, transwell migration, and Matrigel invasion assays. Immunofluorescence for vinculin or paxillin visualizes focal adhesions, and MTS or Annexin V assays assess proliferation and apoptosis. This ITGB3 knockout model is ideal for renal cell carcinoma research, integrin-targeted therapy testing, and metastasis studies. For further details, please contact Ascent Research.
